Skip to Main Content

Author Details

Malaka Ameratunga
Australia Central Clinical School, Monash University
2014
27
12
PMIDPaper TitleJournal TitlePublished Year
37852320Globe Salvage and Vision Preservation by Neoadjuvant Darovasertib and Crizotinib in Uveal Melanoma.Ophthalmol Retina2024
36906655UHRF1/UBE2L6/UBR4-mediated ubiquitination regulates EZH2 abundance and thereby melanocytic differentiation phenotypes in melanoma.Oncogene2023
35018664Dramatic clinical response in the treatment of small cell glioblastoma multiforme.J Clin Pharm Ther2022
35404015A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.Invest New Drugs2022
35717027Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors.J Immunother Cancer2022
34549181Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin.Neurooncol Adv2021
32332017Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials.Clin Cancer Res2020
31985841Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma.J Clin Pharm Ther2020
32066817The kinase polypharmacology landscape of clinical PARP inhibitors.Sci Rep2020
32989226First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.Br J Cancer2020
30224338To Cycle or Fight-CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity.Clin Cancer Res2019
29224898Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.Clin Oncol (R Coll Radiol)2018
30025230Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials.Eur J Cancer2018
29854316CNS cancer immunity cycle and strategies to target this for glioblastoma.Oncotarget2018
30318071A single-institution prospective evaluation of a neuro-oncology multidisciplinary team meeting.J Clin Neurosci2018
30316017A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials.Eur J Cancer2018
30480778Anti-angiogenic therapy for high-grade glioma.Cochrane Database Syst Rev2018
29511362Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.Clin Med Insights Oncol2018
29227818Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors.Eur J Cancer2018
28257959The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.J Thorac Oncol2017
27104612PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC.PLoS One2016
26936308Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma.J Clin Pharm Ther2016
26119722Fever in melanoma: new drugs or bugs?Clin Microbiol Infect2015
26715138Hypopharyngeal large cell neuroendocrine carcinoma.BMJ Case Rep2015
24655021Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.Expert Opin Biol Ther2014
25135201Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis.Asia Pac J Clin Oncol2014
25242542Antiangiogenic therapy for high-grade glioma.Cochrane Database Syst Rev2014
  • 1 - 27 of 27

Recommended Authors

Northwestern University, Feinberg School of Medicine
Career Start Year 2013
Number of shared co-authors 1
Auckland City Hospital
Career Start Year 2010
Number of shared co-authors 8
Oncology Center of Excellence
Career Start Year 2008
Number of shared co-authors 0
Northwestern University
Career Start Year 2005
Number of shared co-authors 1
University of California san francisco
Career Start Year 2005
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 1
Yale School of Medicine
Career Start Year 2003
Number of shared co-authors 0
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 1
Medical University of Vienna
Career Start Year 2003
Number of shared co-authors 2
MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 0
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 0
University Hospital Essen
Career Start Year 2002
Number of shared co-authors 0
Peter MacCallum Cancer Centre
Career Start Year 2000
Number of shared co-authors 10
The University of Texas MD Anderson Cancer Center
Career Start Year 2000
Number of shared co-authors 0
University Hospital Tubingen, Eberhard-Karls-University Tubingen
Career Start Year 1998
Number of shared co-authors 1
Princess Margaret Cancer Centre
Career Start Year 1996
Number of shared co-authors 1
The University of Texas MD Anderson Cancer Center
Career Start Year 1996
Number of shared co-authors 1
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 1
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 2
Hunter Medical Research Institute, University of Newcastle
Career Start Year 1993
Number of shared co-authors 4
Brain Tumor & Neuro-Oncology Cleveland Clinic Main Campus
Career Start Year 1993
Number of shared co-authors 1
David Geffen School of Medicine, University of California Los Angeles
Career Start Year 1992
Number of shared co-authors 1
David Geffen School of Medicine at university of california los angeles
Career Start Year 1991
Number of shared co-authors 1
Huntsman Cancer Institute, University of Utah
Career Start Year 1990
Number of shared co-authors 1
Northwestern University
Career Start Year 1990
Number of shared co-authors 1
Meyer Cancer Center
Career Start Year 1990
Number of shared co-authors 0
Lehigh Valley Topper Cancer Institute
Career Start Year 1990
Number of shared co-authors 1
University of Virginia Health System
Career Start Year 1987
Number of shared co-authors 0
University of Melbourne
Career Start Year 1986
Number of shared co-authors 1
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 0

Collaborators

The Institute for Cancer Research
Co-authored papers 7
The Institute of Cancer Research
Co-authored papers 3
Olivia Newton-John Cancer Research Institute
Co-authored papers 3
Olivia Newton-John Cancer Research Institute
Co-authored papers 2
Kresge Eye Institute/Wayne State University Department of Ophthalmology
Co-authored papers 2
Peter MacCallum Cancer Centre
Co-authored papers 2
University of California los angeles
Co-authored papers 2
Austin Hospital
Co-authored papers 2
Churchill Hospital
Co-authored papers 2
Olivia Newton-John Cancer Research Institute
Co-authored papers 2
The Institute of Cancer Research
Co-authored papers 1
Ovarian Cancer Action Research Centre, Imperial College London
Co-authored papers 1
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Northern Hospital
Co-authored papers 1
University of Toronto
Co-authored papers 1
The Institute of Cancer Research
Co-authored papers 1
The Institute for Cancer Research
Co-authored papers 1
Research Institute in Oncology and Hematology
Co-authored papers 1
Co-authored papers 1
Royal Melbourne Hospital
Co-authored papers 1
Olivia Newton-John Cancer Research Institute
Co-authored papers 1
The Institute of Cancer Research
Co-authored papers 1